Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trialFlorence Ader, Raphaël Clère-Jehl, Gil Verschelden et al.|The Lancet Infectious Diseases|2021Cited by 344
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Bryan J. McVerry, Andreas M. Schmitt et al.|Nature Communications|2021Cited by 295
SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubuleAlexis Wérion, David Vancraeynest, Sophie Piérard et al.|Kidney International|2020Cited by 236
Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patientsVirginie Montiel, Jean‐Luc Balligand, Irina Lobysheva et al.|EBioMedicine|2022Cited by 99
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trialsCathrine Axfors, Bryan J. McVerry, Andreas M. Schmitt et al.|medRxiv|2020Cited by 79